SAMHD1 and ovarian carcinoma: Overall, clinical data allowed us to propose SAMHD1 as a prognostic marker in ovarian cancer, whose function might putatively induce antitumoral innate immune response, as demonstrated in vitro in cell lines (Figure 3C).